Skip to main content
Premium Trial:

Request an Annual Quote

Quidel Acquires Diagnostic Hybrids for $130M

NEW YORK (GenomeWeb News) – Point-of-care diagnostic test provider Quidel said today that it has agreed to acquire Diagnostic Hybrids for approximately $130 million.

Diagnostic Hybrids, based in Athens, Ohio, manufactures and sells direct fluorescent in vitro diagnostic assays used in hospital and reference laboratories for a variety of diseases, including viral respiratory infections, herpes, chlamydia, and thyroid disease.

Quidel, based in San Diego, said that Diagnostic Hybrids' assays will broaden its current portfolio into complementary non-seasonal infectious and autoimmune diseases and help diversify its revenue base.

"In the hospital segment, fluorescent assays fill a customer need that is not met by point-of-care lateral flow or molecular diagnostics assays," Douglas Bryant, Quidel's president and CEO, said in a statement.

Bryant added that the combined company will offer "a continuum of diagnostic tests for triaging patients, confirming diagnoses, and providing actionable results to improve patient care."

Quidel said that it plans to operate Diagnostic Hybrids as a separate subsidiary, and that it expects the acquisition to close in current quarter.

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.